NASDAQ:DBVT DBV Technologies Q1 2024 Earnings Report $10.00 +0.29 (+2.99%) Closing price 03:59 PM EasternExtended Trading$10.30 +0.30 (+3.00%) As of 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast DBV Technologies EPS ResultsActual EPS-$1.40Consensus EPS -$2.20Beat/MissBeat by +$0.80One Year Ago EPSN/ADBV Technologies Revenue ResultsActual Revenue$1.41 millionExpected Revenue$3.20 millionBeat/MissMissed by -$1.79 millionYoY Revenue GrowthN/ADBV Technologies Announcement DetailsQuarterQ1 2024Date5/7/2024TimeN/AConference Call DateTuesday, May 7, 2024Conference Call Time4:00PM ETUpcoming EarningsDBV Technologies' Q2 2025 earnings is scheduled for Tuesday, July 29, 2025, with a conference call scheduled on Friday, August 1, 2025 at 6:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress ReleaseEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release DBV Technologies Earnings HeadlinesDBV Technologies Begins Pivotal Peanut Allergy Study, Aims for 2026 FDA Submission.July 9, 2025 | msn.com12 Best Performing NASDAQ Stocks According to AnalystsJuly 8, 2025 | insidermonkey.comThis Could Be the Most Profitable Season of Your LifeInstitutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the same point in every cycle when crypto enters its most explosive phase — and two experts are showing how to ride it. Inside The Crypto Code Workshop, you’ll get their step-by-step system and $10 in free Bitcoin for attending.July 18 at 2:00 AM | Crypto Swap Profits (Ad)DBV Technologies S.A. (DBVT) - Yahoo FinanceJuly 4, 2025 | finance.yahoo.comDBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old - MorningstarJune 26, 2025 | morningstar.comMDBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years OldJune 26, 2025 | uk.finance.yahoo.comSee More DBV Technologies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like DBV Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DBV Technologies and other key companies, straight to your email. Email Address About DBV TechnologiesDBV Technologies (NASDAQ:DBVT) is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapy solutions for food and environmental allergies. At the core of its research is the Viaskin® platform, an epicutaneous patch technology designed to deliver micro-doses of allergen through intact skin to elicit desensitization while minimizing systemic exposure. The company’s lead program, Viaskin Peanut, is being evaluated in pivotal Phase III trials in both the United States and Europe, offering a novel approach to addressing one of the most common and potentially severe food allergies in children and adults. Beyond its peanut allergy program, DBV Technologies is advancing additional Viaskin immunotherapies targeting cow’s milk allergy, atopic dermatitis associated with food allergies, and other allergens such as hen’s egg and cat dander. These programs are at various stages of clinical development, highlighting the platform’s versatility and the company’s commitment to addressing unmet medical needs in allergy care. DBV collaborates with leading academic institutions and regulatory authorities to design and execute trials that meet rigorous safety and efficacy standards. Founded in 2002 and headquartered in Bagneux, France, DBV Technologies also maintains a presence in Marlborough, Massachusetts, to support its North American operations. The company was co-founded by renowned allergists and scientists, and its leadership team is headed by CEO Marco Zannoni, whose experience spans global product development and regulatory strategy. DBV’s scientific advisory board comprises experts in allergy and immunology, reinforcing its strategic vision to transform the treatment landscape for allergic diseases worldwide.Written by Jeffrey Neal JohnsonView DBV Technologies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Upcoming Earnings NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Intuitive Surgical (7/22/2025)Texas Instruments (7/22/2025)Chubb (7/22/2025)Canadian National Railway (7/22/2025)Capital One Financial (7/22/2025)Danaher (7/22/2025)General Motors (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
